Authors
Jianlin Wu, Haijie Hu, Fuyu Li
Published in
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. Volume 53. Issue 1. Pages 112339. Oct 23, 2026. Epub Oct 23, 2026.
Abstract
Registry-recorded qualitative alpha-fetoprotein (AFP) status may aid prognostic assessment in hepatocellular carcinoma (HCC), but a constant hazard ratio obscures absolute mortality burden, competing causes, and changes over time.
We studied adults with HCC diagnosed during 2010-2015 in the Surveillance, Epidemiology, and End Results database. Index records were selected before AFP classification. Diagnosis-time-adjusted Cox models, AFP-negative-targeted matching, 60-month restricted mean survival time (RMST), cause-specific restricted mean time lost (RMTL), observation weighting, and flexible time-effect analyses were used.
Among 24,234 adults, 17,500 were AFP-positive and 6734 were AFP-negative. Adjusted hazard ratios (HRs) for AFP-negative versus AFP-positive status were 0.729 (95% CI 0.705-0.755) for all-cause mortality and 0.682 (0.657-0.709) for HCC-specific mortality; matched HRs in 6650 pairs were 0.795 (0.766-0.825) and 0.745 (0.715-0.777). AFP-negative patients had 5.73 additional months of overall RMST (5.02-6.45). AFP-positive patients lost 6.31 additional months to HCC death (5.55-7.08), with a 9.40-percentage-point higher five-year HCC-death incidence (7.78-10.97). Observation weighting and histology restriction yielded similar estimates. Piecewise HRs showed lower conditional mortality with AFP negativity during 0-12 and > 12-36 months, near-null associations during >36-60 months, and HRs above 1 during >60-120 months.
Qualitative AFP status distinguished early and five-year HCC mortality burden, but the relative association was not maintained throughout follow-up. These registry estimates support prognosis and case-mix interpretation, not treatment selection.
PMID:
42966037
Bibliographic data and abstract were imported from PubMed on 01 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0